ICRP Publication 106: Radiation Dose to Patients from Radiopharmaceuticals, A Third Adendum to ICRP Publication 53

In this report, the Commission provides biokinetic and dosimetric models for 33 radiopharmaceuticals as well as recommendations related to breast-feeding for mothers, who have undergone a nuclear medicine investigation. The report is based on Addenda 3-9 to ICRP Publication 53. Addenda 3-7 have been available on the ICRP web site (www.icrp.org) as interim reports. The work has been carried out in a joint Task Group of ICRP Committees 2 and 3. This Publication provides biokinetic models, absorbed doses and effective doses for the following radiopharmaceuticals: 11C-acetate, 11C-amino acids, 11C-brain receptor substances, 11C-methionine, 18F-amino acids, 18F-FET, 18F-FDG, 111In-monoclonal antibodies/fragments, 123I-fatty acid (BMIPP, IPPA), 123I-monoclonal antibodies/fragments, 131I-monoclonal antibodies/fragments, and 201Tl-ion. The Publication also provides realistic maximum models for 11C and 18F-substances, for which no specific models are available.

Table of Contents

PREFACE
INTRODUCTION
SELECTION OF RADIOPHARMACEUTICALS
SELECTION OF ORGANS AND TISSUES FOR DOSE CALCULATIONS
BIOKINETIC MODELS AND DATA
METHODS FOR CALCULATING ABSORBED DOSE
EFFECTIVE DOSE
DOSE TO EMBRYO AND FETUS
REFERENCES, MAIN TEXT
ANNEX A. SPECIAL BIOKINETIC AND DOSIMETRIC MODELS
ANNEX B. EXPLANATIONS
ANNEX C. BIOKINETIC MODELS AND DOSE TABLES
ANNEX D. RECOMMENDATIONS ON BREAST-FEEDING INTERRUPTIONS
ANNEX E. RADIATION EXPOSURE OF HANDS IN RADIOPHARMACIES; MONITORING OF THE DOSES AND OPTIMISATION OF PROTECTION